The oncogenic dysregulation of EGFR signal transduction is a common mechanism for driving lung tumors, and many anticancer drugs targeting the molecules in the EGFR pathway have been clinically used for the treatment of NSCLC. This evidence concerns the gene EGFR and non-small cell lung carcinoma.